참고문헌
- Boente MP, Chi DS, Hoskins WJ (1998). The role of surgery in the management of ovarian cancer: primary and interval cytoreductive surgery. Semin Oncol, 25, 326.
-
Bodnar L, Stanczak A, Cierniak S, et al (2014). Wnt/
$\beta$ -catenin pathway as a potential prognostic and predictive marker in patients with advanced ovarian cancer. J Ovarian Res, 7, 16. https://doi.org/10.1186/1757-2215-7-16 - Bookman MA, Darcy KM, Clarke-Pearson D, Boothby RA, Horowitz IR (2003). Evaluation of monoclonal humanized anti-HER2 antibody, trastuzumab, in patients with recurrent or refractory ovarian or primary peritoneal carcinoma with overexpression of HER2: a phase II trial of the Gynecologic Oncology Group. J Clin Oncol, 21, 283-90. https://doi.org/10.1200/JCO.2003.10.104
- Bosmuller H, Haitchi-Petnehazy S, Webersinke G, et al (2011). Intratumoral lymphocyte density in serous ovarian carcinoma is superior to ERCC1 expression for predicting response to platinum-based therapy. Virchows Arch, 459, 183-91. https://doi.org/10.1007/s00428-011-1110-1
- Chumworathayi B (2013) Personalized cancer treatment for ovarian cancer. Asian Pac J Cancer Prev, 14, 1661-4. https://doi.org/10.7314/APJCP.2013.14.3.1661
- Crawford SC, Vasey PA, Paul J, et al (2005). Does aggressive surgery only benefit patients with less advanced ovarian cancer? Results from an international comparison within the SCOTROC-1 Trial. J Clin Oncol, 23, 8802. https://doi.org/10.1200/JCO.2005.02.1287
- de Graeff P, Crijns AP, Ten Hoor KA, et al (2008). The ErbB signalling pathway; protein expression and prognostic value in epithelial ovarian cancer. Br J Cancer, 99, 341-9. https://doi.org/10.1038/sj.bjc.6604471
- de Graeff P, Crijns AP, de Jong S, et al (2009). Modest effect of p53, EGFR and HER-2/neu on prognosis in epithelial ovarian cancer: a meta-analysis. Br J Cancer, 101, 149-59. https://doi.org/10.1038/sj.bjc.6605112
- de Toledo MC, Sarian LO, Sallum LF, et al (2013). Analysis of the contribution of immunologically-detectable HER2, steroid receptors and of the “triple-negative” tumor status to disease-free and overall survival of women with epithelial ovarian cancer. Acta Histochem, 116, 440-7.
- Gadducci A, Zola P, Landoni F, et al (1995). Serum half-life of CA125 during early chemotherapy as an independent prognostic variable for patients with advanced epithelial ovarian cancer: results of a multicentric Italian study. Gynecol Oncol, 7, 42-7.
- Hammond ME (2011). ASCO-CAP guidelines for breast predictive factor testing: an update. Appl Immunohistochem Mol Morphol, 19, 499-500. https://doi.org/10.1097/PAI.0b013e31822a8eac
- Han Y, Huang H, Xiao Z, et al (2012). Integrated analysis of gene expression profiles associated with response of platinum/ paclitaxel-based treatment in epithelial ovarian cancer. PLoS One, 7, 52745. https://doi.org/10.1371/journal.pone.0052745
- Hogdall EV, Christensen L, Hogdall CK, et al (2007). Prognostic value of estrogen receptor and progesterone receptor tumor expression in Danish ovarian cancer patients: from MALOVA ovarian cancer stuy. Oncol Rep, 18, 1051-9.
- Lassus H, Leminen A, Cheng G, et al (2004). ERBB2 amplification is superior to protein expression status in predicting patient outcome in serous ovarian carcinoma. Gynecol Oncol, 92, 31-9. https://doi.org/10.1016/j.ygyno.2003.10.010
- Lassus H, Sihto H, Leminen A, et al (2006). Gene amplification, mutation, and protein expression of EGFR and mutations of ERBB2 in serous ovarian carcinoma. J Mol Med, 84, 671-81. https://doi.org/10.1007/s00109-006-0054-4
- Lee KR, Tavassoli FA, Prat J, et al (2003). Surface epithelialstromal tumours. In: Tavassoli FA, Devilee P editors. World Health Organization classification of tumours. pathology and genetics. tumours of the breast and female genital organs. Lyon. IARC Press, 117-45.
- Lenhard M, Tereza L, Heublein S, et al (2012). Steroid hormone receptor expression in ovarian cancer: progesterone receptor B as prognostic marker for patients survival. BMC Cancer, 12, 553. https://doi.org/10.1186/1471-2407-12-553
- Liu N, Wang X, Sheng X (2010). The clinicopathological characteristics of triple-negative epithelial ovarian cancer. J Clin Pathol, 63, 240-3. https://doi.org/10.1136/jcp.2009.071985
- Miller AB, Hoogstraten B, Staquet M, Winkler A (1981). Reporting results of cancer treatment. Cancer, 47, 207-14. https://doi.org/10.1002/1097-0142(19810101)47:1<207::AID-CNCR2820470134>3.0.CO;2-6
- Nielsen JS, Jakobsen E, Holund B, Bertelsen K, Jakobsen A (2004). Prognostic significance of p53, Her-2, and EGFR overexpression in borderline and epithelial ovarian cancer. Int J Gyn Cancer, 14, 1086-96. https://doi.org/10.1111/j.1048-891X.2004.14606.x
- Noske A, Schwabe M, Weichert W, et al (2011). An intracellular targeted antibody detects EGFR as an independent prognostic factor in ovarian carcinomas. BMC Cancer, 11, 294. https://doi.org/10.1186/1471-2407-11-294
- Psyrri A, Kassar M, Yu Z, et al (2005). Effect of epidermal growth factor receptor expression level on survival in patients with epithelial ovarian cancer. Clin Cancer Res, 11, 8637-43. https://doi.org/10.1158/1078-0432.CCR-05-1436
- Ray-Coquard I, Guastalla JP, Allouache D, et al (2009). HER2 Overexpression/amplification and trastuzumab treatment in advanced ovarian cancer: A GINECO Phase II Study. Clin Ovarian Cancer, 2, 17-22. https://doi.org/10.1016/S1941-4390(11)70077-0
- Saxena R, Dwivedi A (2012). ErbB family receptor inhibitors as therapeutic agents in breast cancer: current status and future clinical perspective. Med Res Rev, 32, 166-215. https://doi.org/10.1002/med.20209
- Siegel R, Ma J, Zou Z, Jemal A (2014) Cancer statistics, 2014. CA Cancer J Clin, 64, 9. https://doi.org/10.3322/caac.21208
- Sinn BV, Darb-Esfahani S, Wirtz RM, et al (2011) Evaluation of a hormone receptor-positive ovarian carcinoma subtype with a favourable prognosis by determination of progesterone receptor and oestrogen receptor 1 mRNA expression in formalin-fixed paraffin-embedded tissue. Histopathol, 59, 918-27. https://doi.org/10.1111/j.1365-2559.2011.04028.x
- Skirnisdottir I, Sorbe B, Seidal T (2001). The growth factor receptors HER-2/neu and EGFR, their relationship, and their effects on the prognosis in early stage (FIGO I-II) epithelial ovarian carcinoma. Int J Gyn Cancer, 11, 119-29. https://doi.org/10.1046/j.1525-1438.2001.011002119.x
- Steffensen KD, Waldstrom M, Jeppesen U, et al (2007). The prognostic importance of cyclooxygenase 2 and HER2 expression in epithelial ovarian cancer. Int J Gynecol Cancer, 17, 798-807. https://doi.org/10.1111/j.1525-1438.2006.00855.x
- Suprasert P, Chalapati W. Detection of recurrence in a surveillance program for epithelial ovarian cancer. Asian Pac J Cancer Prev, 14, 7193-6. https://doi.org/10.7314/APJCP.2013.14.12.7193
- Tuefferd M, Couturier J, Penault-Llorca F, et al (2007). HER2 status in ovarian carcinomas: a multicenter GINECO study of 320 patients. PLoS One, 2, 1138. https://doi.org/10.1371/journal.pone.0001138
- Verri E, Guglielmini P, Puntoni M, et al (2005). HER1/ neu oncoprotein overexpression in epithelial ovarian cancer:evaluation of its prevalence and prognostic significance. Clinical study. Oncology, 68, 154-61. https://doi.org/10.1159/000086958
- Winter WE 3rd, Maxwell GL, Tian C, et al (2007). Prognostic factors for stage III epithelial ovarian cancer: a Gynecologic Oncology Group Study. J Clin Oncol, 25, 3621. https://doi.org/10.1200/JCO.2006.10.2517
- Yan B, Choo SN, Mulyadi P, et al (2011) Dual-colour HER2/ chromosome 17 chromogenic in situ hybridisation enables accurate assessment of HER2 genomic status in ovarian tumours. J Clin Pathol, 64, 1097-101. https://doi.org/10.1136/jclinpath-2011-200082
- Yigit S, Demir L, Tarhan MO, et al (2012). The clinicopathological significance of Bax and Bcl-2 protein expression with tumor infiltrating lymphocytes in ovarian carcinoma. Neoplasma, 59, 475-85. https://doi.org/10.4149/neo_2012_061
- Young RC, Decker DG, Wharton JT, et al (1983). Staging laparotomy in early ovarian cancer. JAMA, 250, 3072. https://doi.org/10.1001/jama.1983.03340220040030
- Zhao D, Zhang F, Zhang W, et al (2013). Prognostic role of hormone receptors in ovarian cancer: a systematic review and meta-analysis. Int J Gyn Cancer, 23, 25-33. https://doi.org/10.1097/IGC.0b013e3182788466
- Ziolkowska-Seta I, Madry R, Kraszewska E, et al (2009). P53, BCL-2 and BAX analysis in 199 ovarian cancer patients treated with taxane-platinum regimens. Gynecol Oncol, 112, 179-84. https://doi.org/10.1016/j.ygyno.2008.09.008
- Zivanovic O, Sima CS, Iasonos A, et al (2009). Exploratory analysis of serum CA-125 response to surgery and the risk of relapse in patients with FIGO stage IIIC ovarian cancer. Gynecol Oncol, 115, 209. https://doi.org/10.1016/j.ygyno.2009.06.038
피인용 문헌
- Salivary Her2/neu Levels in Differentiation of Oral Premalignant Disorders and Oral Squamous Cell Carcinomas vol.16, pp.14, 2015, https://doi.org/10.7314/APJCP.2015.16.14.5773
- pathway is associated with Advanced Ovarian Cancer in Saudi Patients vol.16, pp.14, 2015, https://doi.org/10.7314/APJCP.2015.16.14.5807
- Association of HER2 codon 655 polymorphism with ovarian cancer vol.37, pp.6, 2016, https://doi.org/10.1007/s13277-015-4609-2
- Relationship between HER2 and JAK/STAT-SOCS3 signaling pathway and clinicopathological features and prognosis of ovarian cancer vol.18, pp.5, 2017, https://doi.org/10.1080/15384047.2017.1310343
- The prognostic value of HER2 in ovarian cancer: A meta-analysis of observational studies vol.13, pp.1, 2018, https://doi.org/10.1371/journal.pone.0191972
- Prognostic Value of HER-2/neu Gene Amplification in Epithelial Ovarian Carcinoma pp.0975-6434, 2018, https://doi.org/10.1007/s13224-018-1186-5